Wheaton Franciscan Healthcare

Introduction: Post-acute care (PAC) facilities across Montana, Nebraska, and North Dakota participated in the American Heart Association’s (AHA) Tri-State Mission: Lifeline Stroke PAC Initiative, a quality improvement initiative focused on improving stroke rehabilitation across Midwest states from 2022 to 2024. Participating facilities agreed to implement evidence-based practice outlined by AHA’s PAC Stroke Program Standards. Purpose: The Tri-State Mission: Lifeline Stroke PAC Initiative aimed to assist facilities to implement evidenced-based care and track key performance measures and outcome metrics to facilitate ongoing quality improvement. 15 skilled nursing facilities, 7 inpatient rehabilitation facilities, and 15 critical access hospitals participated across three states with emphasis on developing programs in rural communities. Methods: Participating facilities collected quarterly data for six clinical measures and three outcome metrics detailed in the PAC stroke program standards. Data was entered on the Quality and Certification Tool (QCT) platform to track progress and compare to other sites in the initiative. Group data was reviewed with facilities each quarter on virtual learning collaboratives. Results: Positive improvements were reported in four measures: percentage of patients with aphasia receiving speech therapy, patients receiving comprehensive stroke education, patients with impaired mobility who are on a VTE prophylaxis plan, and patients receiving a phone call within 3 business days of discharge. Performance remained consistent in two measures: percentage of patients receiving a depression screening and patients that had an admission assessment completed by an MD or APP in the first 24 hours. Outcome metrics of average length of stay, number of patients, and discharge disposition remained consistent. Conclusion: Focused quality improvement efforts can positively impact key measures and metrics in post-acute stroke programs. While positive trends were observed in four measures, further evaluations need to be done with larger patient volumes and extended periods of time.

Pulmonary embolism (PE) associated with Mycoplasma pneumoniae pneumonia (MPP) in children has already attracted more attention. CT pulmonary angiography (CTPA) has been the preferred method for diagnosing PE, but it has some limitations, especially for children. Dual-energy spectral CT has been used in diagnosing PE in adults. To evaluate the application of dual-energy spectral CT in diagnosing PE in children with MPP. Eighty-three children with MPP and highly suspected PE, underwent CTPA with spectral imaging mode, 25 children were diagnosis with PE. Noise, clot-to-artery contrast-to-noise ratio, image quality and diagnosis confidence were calculated and assessed on nine monochromatic image sets (40 to 80keV). CTPA images were observed for the presence, localization and embolic degrees of PE. Clots were divided into intra- and extra-consolidation clots. For extra-consolidation clots, iodine concentration (IC) of perfusion defects and normal lung, perfusion defects of four children before and after the treatment were measured and compared. For intra-consolidation clots, IC of consolidation areas with clots and consolidation areas without clot were measured and compared. The optimal energy level for detecting PE in children was 55keV. 116 clots (29 extra-consolidations) were found, IC of defect regions was 0.69 ± 0.28mg/mL (extra-consolidations) and 0.90 ± 0.23mg/mL (intra-consolidations), both significantly lower than the 2.76 ± 0.45mg/mL in normal lungs and 10.25 ± 1.76mg/mL in consolidations without clots (P < 0.001). Significant difference was found in the presence or absence of perfusion defects between occlusive clots and nonocclusive clots (P < 0.001). IC of the perfusion defects significantly increased after treatment (P < 0.001). In dual-energy spectral CTPA, 55keV images optimize PE detection for children, and MD images quantify pulmonary blood flow of PE, and may help to detect small clots and quantify embolic degrees.

Leaders play a crucial role in implementing and sustaining changes in clinical practice, yet there is limited evidence on the strategies to engage them in team problem solving and communication. Examine the impact of an intervention focused on facilitating leadership during daily huddles on optimizing team-based care and improving outcomes. Cluster-randomized trial using intention-to-treat analysis to measure the effects of the intervention (n = 13 teams) compared with routine practice (n = 16 teams). Twenty-nine primary care clinics affiliated with a large integrated health system in the upper Midwest; representing differing practice types and geographic settings. Full-day leadership training retreat for team leaders to facilitate of care team huddles. Biweekly coaching calls and two site visits with an assigned coach. Primary outcomes of team development and function were collected, pre- and post-intervention using surveys. Patient satisfaction and quality outcomes were compared pre- and post-intervention as secondary outcomes. Leadership engagement and adherence to the intervention were also assessed. A total of 279 pre-intervention and 272 post-intervention surveys were completed. We found no impact on team development (- 0.98, 95% CI (- 3.18, 1.22)), improved team credibility (0.18, 95% CI (0.00, 0.35)), but worse psychological safety (- 0.19, 95% CI (- 0.38, 0.00)). No differences were observed in patient satisfaction; however, results were mixed among quality outcomes. Post hoc analysis within the intervention group showed higher adherence to the intervention was associated with improvement in team coordination (0.47, 95% CI (0.18, 0.76)), credibility (0.28, 95% CI (0.02, 0.53)), team learning (0.42, 95% CI (0.10, 0.74)), and knowledge creation (0.74, 95% CI (0.35, 1.13)) compared to teams that were less engaged. Results of this evaluation showed that leadership training and facilitation were not associated with better team functioning. Additional components to the intervention tested may be necessary to enhance team functioning. Clinicaltrials.gov Identifier NCT03062670. Registration Date: February 23, 2017. URL: https://clinicaltrials.gov/ct2/show/NCT03062670.

EECP (Enhanced External Counterpulsation) has been approved by the FDA (Food and Drug Administration) for management of refractory angina (class IIb). EECP uses 3 sets of pneumatic cuffs that sequentially contract during diastole, increasing aortic diastolic pressure, augmenting coronary blood flow and central venous return. EECP has been shown to improve angina symptoms, reduce nitroglycerin use, and improve exercise tolerance in patients with chronic stable angina. EECP has also been shown to be safe and beneficial in patients with symptomatic stable congestive heart failure. It's been postulated that cardiac benefits of EECP are mediated though VEGF and Nitric oxide mediated vasodilatation and angiogenesis. Recently, the Food and Drug Administration (FDA) approved EECP therapy for heart failure patients.

As patients are increasingly becoming health literate, it is common for them to utilize publically available symptom checker applications prior to seeing a health-care provider.1 Limited analysis to date has focused on symptom checker's diagnostic accuracy using predetermined clinical vignettes, with varying results depending on disease severity, commonality and subject matter.2,3 Critiques of the original studies have called for consecutive, prospective, real patient cases with well-validated diagnosis as a criterion paramount for head-to-head performance of symptom checkers and physicians.

Matrix metaloproteinase-2 (MMP-2) is an extracellular Zn2+ protease specific to type I and IV collagens. Its expression is associated with several inflammatory, degenerative, and malignant diseases. Conformational properties, domain movements, and interactions between MMP-2 and its associated metal ions were characterized using a 1.0 µs molecular dynamics simulation. Dihedral principle component analysis revealed ten families of conformations with the greatest degree of variability occurring in the link region connecting the catalytic and hemopexin domains. Dynamic cross-correlation analysis indicated domain movements corresponding to the opening and closing of the hemopexin domain in relation to the fibronectin and catalytic domains facilitated by the link region. Interaction energies were calculated using the molecular mechanics Poisson Boltzman surface area-interaction entropy (MMPBSA-IE) analysis method and revealed strong binding energies for the catalytic Zn2+ ion 1, Ca2+ ion 1, and Ca2+ ion 3 with significant conformational stability at the binding sites of Zn2+ ion 1 and Ca2+ ion 1. Ca2+ ion 2 diffuses freely away from its crystallographically defined binding site. Zn2+ ion 2 plays a minor role in conformational stability of the catalytic domain while Ca2+ ion 3 is strongly attracted to the highly electronegative sidechains of the Asp residues around the central β-sheet core of the hemopexin domain; however, the interacting residue sidechain carboxyl groups are outside of Ca2+ ion 3′s coordination sphere.

Matrix Metaloproteinase-2 (MMP-2) is an extracellular Zn2+ protease specific to type I and IV collagens. Its expression is associated with several inflammatory, degenerative, and malignant diseases. Conformational properties, domain movements, and interactions between MMP-2 and its associated metal ions were characterized using a 1.0 &amp;micro;s molecular dynamics simulation. Dihedral principle component analysis revealed 10 families of conformations with the greatest degree of variability occurring in the link region connecting the catalytic and hemopexin domains. Dynamics cross correlation analysis indicated domain movements corresponding to opening and closing of the hemopexin domain in relation to the fibronectin and catalytic domains facilitated by the link region. Interaction energies were calculated using the MMPBSA-interaction entropy analysis method and revealed strong binding energies for the catalytic Zn2+ ion 1, Ca2+ ion 1, and Ca2+ ion 3 with significant conformational stability at the binding sites of Zn2+ ion 1 and Ca2+ ion 1. Ca2+ ion 2 diffuses freely away from its crystallographically defined binding site. Zn2+ ion 2 plays a minor role in conformational stability of the catalytic domain while Ca2+ ion 3 is strongly attracted to the highly electronegative sidechains of the Asp residues around the central &amp;beta;-sheet core of the hemopexin domain.